Hemorrhage/Bleeding Antidotes and Reversal Agents    body {font-family: 'Open Sans', sans-serif;}

### Hemorrhage/Bleeding Antidotes and Reversal Agents

**Amicar (Aminocaproic Acid):**  
To prevent bleeding

<table class="MsoTableGrid" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 467.5pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="623"><p class="MsoNormal"><strong><span style="font-size: 11.0pt;">Class: </span></strong><span style="font-size: 11.0pt;"><span style="color: #4d5156; background: white;">Antifibrinolytic Agent</span></span><span style="font-size: 11.0pt;"><br></span><span style="font-size: 11.0pt;">Amicar has been replaced by tranexamic acid (TXA) in most medical institutions (esp. cardiac surgery)<br>because TXA is 10x more potent.<br><strong>MOA: </strong>Prevents the conversion of plasminogen to plasmin-prevents clot breakdown<br><strong>Cardiac surgery dosing:</strong><br>5 grams post-induction<br>5 grams after heparinizing the patient<br>5 grams post protamine bolus<br>For details, refer to “Amicar (Aminocaproic Acid) for Bleeding” in this app.</span></p></td></tr></tbody></table>

**  
Andexxa (andexanet alfa):**  
Antidote for Eliquis and Xarelto

<table class="MsoTableGrid" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 467.5pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="623"><p class="MsoNormal"><strong><span style="font-size: 11.0pt;">Class: </span></strong><span style="font-size: 11.0pt;"><em><span style="color: black; font-style: normal;">Factor Xa Inhibitor Antidotes</span></em></span><span style="font-size: 11.0pt;"><br></span><span style="font-size: 11.0pt;">Andexxa is very expensive, and Kcentra or FEIBA is cheaper and more available.<br><strong><span style="color: #222222; background: white;">Indication: </span></strong><span style="color: black; background: white;">When reversal of anticoagulation is needed due to </span><span style="color: red; background: white;">life-threatening or uncontrolled bleeding from Apixaban or Rivaroxaban.</span><span style="color: black; background: white;"><br><strong>MOA: </strong>It competes with endogenous factor Xa to bind with factor Xa inhibitors, thus elevating free endogenous factor Xa levels.<br></span>It also binds and inhibits the activity of the Tissue Factor Pathway Inhibitor (TFPI).<br><strong><span style="color: black; background: white;">Dosing: </span></strong><span style="color: black; background: white;">For more details, refer to “Andexxa (andexanet alfa)” in this app.</span></span></p></td></tr></tbody></table>

**  
DDAVP (Desmopressin):**  
Helps control acute bleeding caused by the novel anticoagulants

<table class="MsoTableGrid" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 467.5pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="623"><p class="MsoNormal"><strong><span style="font-size: 11.0pt; color: black; background: white;">Class: </span></strong><span style="font-size: 11.0pt; color: black; background: white;">Vasopressin-Related<br></span><span style="font-size: 11.0pt; color: black;">DDAVP and TXA are both gaining popularity for the early treatment in reversing anticoagulation in bleeding patients ( <span style="background: white;">especially by antiplatelet anticoagulants).</span><br><strong><span style="background: white;">MOA: </span></strong>Increases circulating levels </span><span style="font-size: 11.0pt;">of factor VIII and von Willebrand factor (vWf) by stimulating the release of vWf from the endothelial cells (within the walls of blood vessels).<br></span><strong><span style="font-size: 11.0pt; color: black; background: white;">Dosing: </span></strong><span style="font-size: 11.0pt;">0.3mcg/kg x 1<br></span><span style="font-size: 11.0pt; color: black; background: white;">For more details, refer to <em>“DDAVP (Desmopressin)” </em>in this app.</span></p></td></tr></tbody></table>

**  
FEIBA (activated PCC):**  
For prophylaxis or severe bleeding in anticoagulated patients.  
It can be used for bleeding patients who are anticoagulated by Eliquis and Xarelto.

<table class="MsoTableGrid" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 467.5pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="623"><p class="MsoNormal"><span style="font-size: 11.0pt; color: black; background: white;">Stands for </span><strong>F</strong>actor <strong>E</strong>ight (VIII) <strong>I</strong>nhibitor <strong>B</strong>ypassing <strong>A</strong>ctivity (FEIBA).<br><strong><span style="font-size: 11.0pt; color: #192027;">Class: </span></strong><strong><span style="font-size: 11.0pt; color: #192027; font-weight: normal;">Anti-inhibitor coagulant complex</span></strong><span style="font-size: 11.0pt;"><br><span style="color: black; background: white;">It is an “activated” PCC (aPCC).<br></span><span style="color: black;">Prothrombin Complex Concentrate = PCC</span><span style="color: black; background: white;"><br></span><span style="color: black;">Contains clotting factors 2,7,9,10 and protein C (factor 7 is activated)<span style="background: white;"><br><strong>Do NOT </strong>confuse aPPC with PCCs (Kcentra)<br><strong>Note: </strong>FEIBA was created to bypass FVIII and FIX inhibitors and restore proper coagulation by increasing thrombin further down the coagulation cascade.<br></span></span><strong><span style="color: #19191a;">Indications:<br></span>For the use in hemophilia A and B patients with inhibitors for:</strong><br>Control and prevention of bleeding episodes.<br>Perioperative management<br>Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.<br><br>Depending on institution protocols or situations, <span style="color: red;">FEIBA may be the first option for eminent life-threatening bleeding in patients taking:</span><br>Rivaroxaban<br>Apixaban<br>Edoxaban<br>Dabigatran<strong><br>Dosing: </strong>50-100 units/kg<br>For more details, refer to the two <em>FEIBA files </em>in this app.</span></p></td></tr></tbody></table>

**  
FFP (Fresh Frozen Plasma)**

<table class="MsoTableGrid" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 467.5pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="623"><p class="MsoNormal"><span style="font-size: 11.0pt; color: black;">Sometimes referred to as “Plasma.”<br>FFP has ALL coagulation factors<br>FFP is free of RBCs, leukocytes, and platelets.<br>FFP is efficacious for treating deficiencies of factors II, V, VII, IX, X, and XI.<br><strong><br>Most Popular Indications:</strong><br>PT &gt; 1.5 (&gt;18); Normal is 11-14 secs<br>PTT &gt; 1.5 (55-60) Normal is 30-45 secs<br>One of the antidotes for Coumadin (warfarin).<br>Given after 4 units of PRBCs (FFP to PRBC ratio: 1:4)<br>Patients with documented coagulation factor deficiencies and active bleeding or who are about to undergo an invasive procedure.<br></span><strong><span style="font-size: 11.0pt; color: black;">1 unit: </span></strong><span style="font-size: 11.0pt; color: black;">volume is 200-250mLs.</span><span style="font-size: 11.0pt;"><br></span><span style="font-size: 11.0pt; color: black;"><br></span><strong><span style="font-size: 11.0pt; color: black;">Doses of FFP:</span></strong><span style="font-size: 11.0pt; color: black;"><br><strong>Standard: </strong>5-10mL/kg<br><strong>Popular: </strong>10mL/kg<br>1-2 units are given for every 4 units of PRBCs.<br><br><strong>2 units (400-500mL) for active bleeding confirmed by:</strong><br>PT &gt; 1.5 (&gt;18 secs)<br>PTT &gt; 1.5 (55-60 secs)<br>Fibrinogen &lt; 100mg/dL<br>2 units (400-500mL)</span><span style="font-size: 11.0pt; color: black;"><br></span><strong><span style="font-size: 11.0pt; color: black;"><br></span></strong><span style="font-size: 11.0pt; color: black;">The fibrinogen in 1 unit of FFP is approximately equal to the amount of fibrinogen found in 2 units of cryoprecipitate.<br></span><span style="font-size: 11.0pt; color: black;">4 Units Plasma increase most factors ~10%.<br>FFP has an INR of around 1.6, so it cannot lower a patient’s INR below 1.7.<br></span><span style="font-size: 11.0pt;"><br></span><span style="font-size: 11.0pt;">For more details, refer to the two <em>FFP (Fresh Frozen Plasma) </em>files in this app.</span></p></td></tr></tbody></table>

**Kcentra:** For moderate to severe bleeding and for the anticoagulated patient.

<table class="MsoTableGrid" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 467.5pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="623"><p class="MsoNormal"><span style="font-size: 11.0pt;">Kcentra is a Prothrombin Complex Concentrate (PCC,4F-PCC)<br>Contains factors 2,7,9,10 as well as <span style="color: black;">antithrombotic Proteins C and S.<br></span><strong>Indications:<br></strong><span style="color: black; background: white;">Adults patients with acute major bleeding</span><strong><span style="color: black;"><br></span></strong><span style="color: black; background: white;">Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin)<br><br></span><strong><span style="color: black;">Possible option for an </span>eminent life-threatening bleed due to:</strong><br>Rivaroxaban (Xarelto)<br>Apixaban (Eliquis)<br>Dabigatran (Pradaxa)<br>Edoxaban<br><em><span style="color: red;">However, PCCs do NOT directly neutralize the activity of new oral anticoagulants.</span></em><br><strong><span style="color: black; background: white;">Dosing: </span></strong></span>12.5-50 units/kg IV<span style="font-size: 11.0pt; color: black; background: white;"><br></span><span style="color: #252525; background: white;">“Kcentra” was the first “NON-activated PCC.”</span><span style="color: black;"><br></span><span style="color: #252525;">Prothrombin Complex Concentrate <span style="background: white;"></span>(PCC) <span style="background: white;">is considered a 2<sup>nd</sup> option behind FEIBA (aPCC) for life threatening bleeds.<br></span></span>For more details, refer to the two <em>Kcentra (Prothrombin Complex Concentrate) files </em>in this app.</p></td></tr></tbody></table>

**Praxbind (idarucizumab):** Antidote for Pradaxa (dabigatran)

<table class="MsoTableGrid" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 467.5pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="623"><p class="MsoNormal"><span style="font-size: 11.0pt;">A monoclonal antibody that directly neutralizes the effects of dabigatran.<br><strong><span style="color: black;">Indications: </span></strong><strong><span style="color: black; font-weight: normal;">When reversal of the anticoagulant effects of dabigatran is needed-</span></strong><span style="color: black;"><br>Emergency surgery/urgent procedures<br>Life-threatening or uncontrolled bleeding</span><br><strong><br>Dosing: </strong><span style="color: black;">5 gr </span></span>ams <span style="font-size: 11.0pt; color: black;">IV x 1, administered as 2 consecutive IV infusions of 2.5-gram vials over 5 minutes each.<br>The second 2.5-gram vial must be administered within 15 minutes of the first vial.<br>Recheck labs.</span><span style="font-size: 11.0pt;"><br></span><span style="font-size: 11.0pt;">FDA trials are currently underway for apixaban, rivaroxaban, and edoxaban.<br>For more details, refer to <em>“ </em></span><em><span style="font-size: 11.0pt;">Praxbind (idarucizumab)” </span></em><span style="font-size: 11.0pt;">in this app.</span></p></td></tr></tbody></table>

**Protamine Sulfate:** Antidote to heparin and LMWH’s (Lovenox and Fragmin)

<table class="MsoTableGrid" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 467.5pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="623"><p class="MsoNormal"><span style="font-size: 11.0pt; color: #192027; background: white;">It can also be used for treating hemorrhage due to severe heparin or LMWH overdose.<br><br><strong>MOA: </strong>Combines with heparin and </span><span style="font-size: 11.0pt; color: #4d5156; background: white;">neutralizes heparin-induced anticoagulation</span><span style="font-size: 11.0pt;"><br><span style="color: #192027; background: white;">Protamine sulfate is a strong basic protein that binds with strongly acidic heparin to produce a stable and inactive complex (salt).<br>Protamine sulfate by itself demonstrates a weak anticoagulant effect.<br><br></span></span><strong><span style="font-size: 11.0pt; color: black; background: white;">Common Doses:<br></span></strong><span style="font-size: 11.0pt; color: black; background: white;">1-1.3 mg of protamine for every 100 units of heparin administered.<br>The amount of protamine required decreases over time as heparin is metabolized.<br></span><br>Remember: The half-life of heparin is 60-90 minutes.<br>Protamine doses vary and depend on the last dose of heparin and how much was administered.<br><strong><br></strong>1-1.5 mg per 100 USP units of heparin; not to exceed 50 mg (except for hearts)<br><br><strong>Doses of protamine (mg to neutralize 100 units of heparin)</strong></p><table class="MsoNormalTable" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 113.4pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="151"><p class="MsoNormal"><strong>Last dose &lt; ½ hour</strong></p></td><td style="width: 187.85pt; border: solid windowtext 1.0pt; border-left: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="250"><p class="MsoNormal">1-1.5 mg/100 units of heparin</p></td></tr><tr><td style="width: 113.4pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="151"><p class="MsoNormal"><strong>30-120 minutes</strong></p></td><td style="width: 187.85pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="250"><p class="MsoNormal">0.5–0.75 mg/100 units of heparin</p></td></tr><tr><td style="width: 113.4pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="151"><p class="MsoNormal"><strong>&gt; 2 hours</strong></p></td><td style="width: 187.85pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="250"><p class="MsoNormal">0.25-0.375 mg/100 units of heparin</p></td></tr></tbody></table><p class="MsoNormal"><span style="font-size: 8.0pt;">protamine (Rx). Drugs &amp; Diseases. Dosing and Uses. Adult. Medscape<br>https://reference.medscape.com/drug/protamine-343746<br><br></span><em>A single dose of 1-5,000 units of heparin for a simple vascular case may not need to be neutralized if the last dose is less than 60 minutes.<br>It is the surgeon’s discretion.<br></em><span style="font-size: 11.0pt;"><br><span style="color: black; background: white;">Assume the half-life of Protamine is about 30 minutes after intravenous injection.</span></span><br><span style="font-size: 11.0pt;"><br><strong><span style="color: red;">Do not bolus protamine: </span></strong></span><span style="font-size: 11.0pt;">It may <span style="color: #202227; background: white;">cause severe hypotension.</span></span><span style="font-size: 11.0pt;"><br></span><span style="font-size: 11.0pt;">Protamine was initially isolated from the sperm heads of salmon and other fish species.<br><br><strong><span style="color: #333333;">Protamine and Post Vasectomy:</span><span style="color: #333333;"><br><span style="background: #F2F2F2;">Nucleoprotamines are a normal component of human sperm cells. Antibodies against these protamines develop in 22 to 33% of patients undergoing elective vasectomy.<br>These antibodies, in turn, have been shown to cross-react with medicinal protamines.</span></span></strong><br><br><strong>Be vigilant after administering to the following patients:</strong><br></span><span style="color: #202227; background: white;">Allergy to fish<br>Previous vasectomy<br>Severe left ventricular dysfunction<br>Abnormal preoperative pulmonary hemodynamics<br></span><span style="color: #333333; background: #F2F2F2;"><strong><br>Anaphylactic reaction in these patients is still very rare.<br>For more details, refer to the three <em>Protamine Sulfate </em>files in this app.</strong></span></p></td></tr></tbody></table>

**Recombinant Human Factor VIIa (NovoSeven, rFVIIa):**  
For achieving hemostasis in hemophilia A and B patients with inhibitors.

<table class="MsoTableGrid" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 467.5pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="623"><p class="MsoNormal"><span style="font-size: 11.0pt;">It works further down the coagulation cascade bypassing the factor VIII and IX inhibitors.<br><strong>Dosing: </strong>35-90 mcg/kg- depending on the cause of bleeding.<br>For more details, refer to <em>“Recombinant Human Factor VIIa (rFVIIa, NovoSeven)” </em>in this app.</span></p></td></tr></tbody></table>

  
**Tranexamic acid (TXA)** **Cyklokapron®** prophylaxis and treatment for bleeds

<table class="MsoTableGrid" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr style="height: 17.5pt;"><td style="width: 467.5pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt; height: 17.5pt;" valign="top" width="623"><p class="MsoNormal"><strong><span style="font-size: 11.0pt; color: #333333;">Class: </span></strong><span style="font-size: 11.0pt; color: #444444; background: white;">antifibrinolytics</span><span style="font-size: 11.0pt;"><br><span style="color: black;">It inhibits fibrinolysis by inhibiting the binding of plasma to fibrin.<br><strong>Indications:</strong><br>To prevent or treat excessive blood loss during surgery and traumas.<br>Help reversal of bleeding with anticoagulants.<br>It is commonly used as prophylaxis in many surgical procedures.<br></span><strong><br>Dosing:</strong><br><strong><span style="color: black;">Common Dose Recommendations of TXA </span></strong><span style="color: black;">(reduced with renal dysfunction)<span class="apple-converted-space"><br></span><strong>Orthopedic Doses: </strong>Range from 1 gram x 2 (before incision and closing)<br><strong>For fibrinolysis: </strong>0.5-1 gram BID or TID <span class="apple-converted-space">I </span></span></span><span class="apple-converted-space">V</span><span style="font-size: 11.0pt; color: black;"><br><strong>Generalized hyperfibrinolysis: </strong>1 gram (15 mg/kg) Q 6-8 hours<br><strong>Cardiac surgery trials–loading or bolus dose: </strong>ranged from 2.5-100 mg/kg.<br><strong>Cardiac surgery maintenance dose: </strong>0.25-4.0 mg/kg/hour over 1-12 hours<br><strong>Orthopedic procedures: </strong>Range from 1 to 2 grams (before incision and closing)<span class="apple-converted-space"><br></span><strong><br>TXA trauma Protocols: </strong>vary<br><span class="apple-converted-space">TXA is </span>commonly mentioned as an option for the early treatment and/or severe bleeding patients </span><span style="font-size: 11.0pt;">who are newer anticoagulants without specific antidotes, including those listed below:</span><span class="apple-converted-space"><span style="font-size: 13.5pt; font-family: 'Open Sans',sans-serif; color: black;"><br></span></span><span style="font-size: 11.0pt; color: black;">Rivaroxaban (Xarelto)<br>Apixaban (Eliquis)<br>Edoxaban (Savaysa)<br>Dabigatran (Pradaxa, Pradax, Prazaxa)<br>Abciximab (Reopro®)<br>Bivalirudin (Angiomax)<br>Clopidogrel (Plavix, Duoplavin)<br>Prasugrel (Effient, Efient)<br>Tirofiban (Aggrastat)<br>Urokinase<br>Vorapaxar Sulfate (Zontivity)</span><strong><span style="font-size: 11.0pt; color: black;"><br></span></strong><strong><span style="font-size: 11.0pt; font-family: 'TimesNewRomanPSMT',serif;"><br>TXA is no longer contraindicated in patients with:</span></strong><span style="font-size: 11.0pt; font-family: 'TimesNewRomanPSMT',serif;"><br>History of CVA/TIA<br>Recent MI (within one year)<br>Coronary vascular stent placed within six months to one year<br><strong><span style="font-family: 'TimesNewRomanPSMT',serif; color: #333333; font-weight: normal;">For more details, refer to t </span></strong><strong><span style="font-family: 'TimesNewRomanPSMT',serif; font-weight: normal;">he three <em><span style="color: #333333;">Tranexamic Acid </span></em><span style="color: #333333;">files in this app.</span></span></strong></span></p></td></tr></tbody></table>

**  
Vitamin K (phytonadione):**  
An antidote to VKAs (Vitamin K Antagonists)-Warfarin

<table class="MsoTableGrid" style="border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 467.5pt; border: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="623"><p class="MsoNormal"><span style="font-size: 11.0pt; color: black;">VKAs </span><span style="font-size: 11.0pt; color: #333333; background: white;">inhibit the synthesis of the vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S.<br><strong>MOA: </strong></span><span style="font-size: 11.0pt;">Leads to the production of functional coagulation factors II, VII, IX, and X that were previously depleted by warfarin.<br><strong><span style="color: black;">Absence of clinical bleeding: </span></strong><span style="color: black;"><span style="background: white;">IV Vitamin: K – may reverse to a normal INR within 6-8 hours.<br></span></span></span><span style="color: black;">Partial effects may be seen in 6 </span><span style="font-family: 'Calibri',sans-serif; color: black;">‐ </span><span style="color: black;">12 hours.</span><span style="font-size: 11.0pt; color: black; background: white;"><br></span><span style="color: black;">Total effect of vitamin K on warfarin reversal occurs approximately 24 hours after administration.<br></span><span style="font-size: 11.0pt;"><br><strong>Vitamin K is insufficient when an URGENT reversal is needed.<br></strong>The liver can’t produce the lacking factors that quickly.<br>In addition to Vitamin K, the missing factors must be replaced with either FFP or PPCs.<br><strong>Dosing:</strong><br><strong>For nonbleeding, elevated INR of 4.5-10: </strong>1.25 mg Vitamin K PO<br><strong>For Major Bleeding: </strong>Vitamin K 5-10 mg IV along with PCCs (Kcentra)<br><strong><span style="color: #333333; font-weight: normal;">For more details, refer to </span></strong><strong><span style="color: #333333;">“ </span></strong><strong><em><span style="color: #333333; font-weight: normal;">Vitamin K” </span></em></strong><strong><span style="color: #333333; font-weight: normal;">in this app for details.</span></strong></span></p></td></tr></tbody></table>

**Other methods, such as dialysis and oral-activated charcoal, are not discussed here.  
**

  

**References:  
**UP Health System - Marquette Pharmacy and Therapeutics Committee Medication Guideline; Urgent Anticoagulant Reversal; 09  
Perioperative Hemostasis –Coagulation for AnesthesiologistC. Marcucci and P. Schoettker; 2015. Pp 211, 213  
UP Health System - Marquette Pharmacy and Therapeutics Committee Medication Guideline  
Urgent Anticoagulant Reversal; 09/13  
https://tinyurl.com/2p9s9ck4  
  
ANTICOAGULANT, THROMBOLYTIC, and ANTI-PLATELET DRUGS  
_Spring 2006 Anticoagulants  
Dr. Janet Fitzakerley_https://tinyurl.com/34z3pnz3  
Reversal of Anticoagulants at UCDMC  
Approved by UCDHS Pharmacy & Therapeutics Committee 3/2017.  
https://www.ucdmc.ucdavis.edu/anticoag/pdf/AnticoagReversal.pdf  
Perioperative Hemostasis –Coagulation for AnesthesiologistC. Marcucci and P. Schoettker; 2015; pp. 123.  
Pocket Anesthesia 3 rd Ed. 2017  
  
R. Urman and J. Ehrenfeld  
ANTICOAGULANTS: THE GUIDE TO REVERSAL  
OHSU Hospital and Clinics Department of Pharmacy Services  
Pharmacy and Therapeutics Committee October, 2011.  
  
https://tinyurl.com/3fun6zda  
  
About Andexxa coagulation factor Xa (recomninant), inactivated -zhzo (accessed 9/2019)  
https://www.andexxa.com/about  
  
FDA Clears First Reversal Agent for Rivaroxaban, Apixaban Anticoagulants (accessed 9/2019)  
Antiplatelet and anticoagulant therapies; May, 2018  
Diagnostic and Interventional Cardiology  
https://tinyurl.com/3vc4yd4a  
  
Beginning to Understand the Cost-effectiveness of Andexxa  
Georgetown Medical Review; Vol. 3, Issue 1, 2019.  
Marina Haque, Michael Gratson, Jodi Woerle, and Fitz Tavernier J  
https://gmr.scholasticahq.com/for-authors  
  
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.  
National Medicine 2013;19:446-451  
Lu G, DeGuzman FR, Hollenbach SJ, et al.  
  
Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.  
Expert Review of Hematology. 2016;9:115-122.  
Ghadimi K, Dombrowski KE, Levy JH, Welsby IJ.  
  
Andexanet Alfa – Antidote for Factor Xa InhibitorsCardiovascular Pharmacology (accessed 10/2022)  
Johnson Francis, MBBS,M  
https://www.youtube.com/watch?v=i0RhdS1BqAU  
  
The role of anticoagulants, antiplatelet agents, and their reversal strategies in the management of intracerebral hemorrhage  
Robert James, Victoras Palys, Jason Lomboy, J. Richard Lamb and Scott Simon.  
_Division of Neurosurgery, Department of Surgery, East Carolina University Brody School of Medicine, Greenville, North Carolina; and Department of Neurosurgery, Virginia Commonwealth University School of Medicine, Richmond, Virginia  
__http://thejns.org/doi/pdf/10.3171/2013.2.FOCUS1328_  
How do you treat bleeding disorders with desmopressin?Postgrad Med J. 2007 Mar; 83(977): 159–163.  
Bülent Özgönenel, Madhvi Rajpurkar, and Jeanne M Lusher  
  
Mannucci P M. Hemostatic drugs. N Engl J Med 1998339245–253.  
Warrier A I, Lusher J M. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease. J Pediatr 1983102228–233  
  
Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction  
Clinical Trials.Gov  
https://clinicaltrials.gov/ct2/show/NCT01382134  
  
Activated Prothrombin Complex Concentrates for the Reversal of Anticoagulant-Associated Coagulopathy  
Nadia I. Awad, PharmD and Craig Cocchio, PharmD, BCPS  
P T. 2013 Nov; 38(11): 696-698, 701.  
  
Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors  
Vasc Health Risk Manag. 2007 Aug; 3(4): 527–531  
Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors  
Vasc Health Risk Manag. 2007 Aug; 3(4): 527–531.  
Geir E Tjønnfjord and Pål Andre Holme.  
  
FDA Approves Hemophilia Drug FEIBA for Bleeding Prophylaxis  
Miriam E. Tucker, December 23, 2013  
http://www.medscape.com/viewarticle/818236  
  
Reversal of the anticoagulant effects of the novel oral anticoagulants for management of bleeding, emergency surgery or overdose for (Dabigatran, Rivaroxaban and Apixaban) by Dr R. Riat  
Consulted with Members of the Thrombosis Committee and reviewed by Hematology Department  
11/2013  
  
Perioperative Hemostasis –Coagulation for Anesthesiologist  
C. Marcucci and P. Schoettker; 2015. Pp 189-195.  
  
Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. Am J Clin Pathol. 2006 Jul;126(1):133-9.  
  
Nascimento B, Callum J, Rubenfeld G, Neto JB, Lin Y, Rizoli S. Clinical review: Fresh frozen plasma in massive bleedings – more questions than answers. Crit Care. 2010;14(1):202. doi: 10.1186/cc8205. Epub 2010 Jan 28. Review. PubMed  
  
Nascimento B, Callum J, Rubenfeld G, Neto JB, Lin Y, Rizoli S. Clinical review: Fresh frozen plasma in massive bleedings – more questions than answers. Crit Care.  
  
Critical Care Compendium  
Fresh Frozen Plasma (FFP)  
https://lifeinthefastlane.com/ccc/fresh-frozen-plasma-ffp/  
  
The Use of 4-Factor Prothrombin Complex Concentrate (Kcentra) in the Urgent Reversal of Vitamin K Antagonists  
Marissa Olson . Pharm.D. Candidate 2015  
KU Department of Pharmacy Practice  
  
Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016Steve Christos, DO, MS \* and Robin Naples, MD †West J Emerg Med. 2016 May; 17(3): 264–270.  
  
Serreira J, DeLos Santos M. The clinical use of prothrombin complex concentrate. J Emerg Med. 2013;44(6):1201–10.  
  
Reversal of Anticoagulants at UCDMC  
Approved by UCDHS Pharmacy & Therapeutics Committee 3/2017.  
https://www.ucdmc.ucdavis.edu/anticoag/pdf/AnticoagReversal.pdf  
  
Perioperative Management of the New Anticoagulants: Novel Drugs and Concept, p5.  
J. Levy MD, P Albalaladejo MD, C. Samama MD, B. Hunt MD, A. Spyropoulos MD, and J. Douketis, MD  
APSF Newsletter, Vol. 32, No. 1. 1-28. June 2017.  
Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomized, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386(9994):680–90.  
  
Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran reversal. N Engl J Med. 373(6):511–20  
  
Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016Steve Christos, DO, MS \* and Robin Naples, MD †West J Emerg Med. 2016 May; 17(3): 264–270.  
  
NovaSeven Package Insert, Nordisk; 2005  
  
Factor VIIa, recombinant (Rx) Dosing  
Medscape  
https://tinyurl.com/3bsxwac3  
  
Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016  
Steve Christos, DO, MS and Robin Naples, MD  
West J Emerg Med. 2016 May; 17(3): 264–270.  
  
Lam MS, Sims-Mcallum RP  
Recombinant factor IIa in the treatment of nonhemophiliac bleeding.  
Ann Pharmacother. 2005; 39:885-891.  
  
Implementing Guidelines for the Institutional Use of Factor VIIa (Recombinant): A Multidisciplinary Solution  
Celeste N. Rudisill; Rebecca H. Hockman; Kathlene A. Degregory; Alan H. Mutnick; Barbara Gail Macik  
Am J Health Syst Pharm. 2006;63(17):1641-1646.  
  
Royal Brompton & Harefield NHS Foundation Trust and the Derbyshire Joint Area Prescribing Committee Guidelines  
https://tinyurl.com/3p7xbnpc  
  
The current place of tranexamic acid in the management of bleeding  
Anaesthesia 2015, 70 (Suppl. 1), 50–53  
B.J. Hunt  
  
PDR-Prescribed Digital Reference  
Accessed 03/2022)  
https://tinyurl.com/5n9abvy7  
  
Alberdi, F., Garcia, I., Atutxa, L., & Zabarte, M. (2014). Epidemiology of Severe Trauma. Medicina Intensiva, 38(9), 580-588.  
  
Tengborn, L., Blomback M., & Berntorp, E. (2014). Tranexamic Acid – An Old Drug Still Going Strong and Making a Revival. Thrombosis Research, 135, 231-242.  
  
Fraga, G. P., Bansal, V., & Coimbra, R. (2010). Transfusion of Blood Products in Trauma: An Update. Journal of Emergency Medicine, 39(2), 253-260. doi:10.1016/j.jemermed.2009.02.034  
  
Spahn, D. R., & Goodnough, L. T. (2013). Alternatives to Blood Transfusion. Lancet, 381, 1855–1865. doi:10.1016/S0140-6736(13)60808-9  
  
Shakur, H., Roberts, I., Bautista, R., Caballero, J., Coats, T., Dewan, Y., . . . Yutthakasemsunt, S. (2010). Effects of Tranexamic Acid on Death, Vascular Occlusive Events, and Blood Transfusion in Trauma Patients with Significant Haemorrhage (CRASH-2): A Randomised, Placebo-Controlled Trial. Lancet, 376, 23-32. doi:10.1016/S0140-6736(10)60835-5  
  
Roberts, I., Shakur, H., Ker, K., & Coats, T. (2012). Antifibrinolytic Drugs for Acute Traumatic Injury. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD004896.pub3  
  
Morrison, J. J., Dubose, J. J., Rasmussen, T. E., & Midwinter, M. J. (2012). Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg, 147(2), 113-119.  
  
Perel, P., Ker, K., Morales Uribe, C. H., & Roberts, I. (2013). Tranexamic Acid for Reducing Mortality in Emergency and Urgent Surgery. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD010245.pub2.Copyright  
  
Guerriero, C., Cairns, J., Perel, P., Shakur, H., & Roberts, I. (2011). Cost-Effectiveness Analysis of Administering Tranexamic Acid to Bleeding Trauma Patients Using Evidence from the CRASH-2 Trial. PLoS ONE, 6(5). doi:10.1371/journal.pone.0018987